Built for the next generation of biotech leaders.
Extend your intelligence using ours. No one dives deeper into dissecting the latest trends than BioCentury, allowing you to better position your company to capitalize on change.
Find licensing and investment opportunities, uncover competitive threats and identify potential partners using our curated database.
Connect with your peers in our global community of C-Suite executives and investors. Our networking events give you unparalleled access to industry leaders who share your need for investments, partnerships and advice.
Use this customizable workspace to filter our warehouse of business intelligence to meet your specific information needs.
Explore some of the ways we can help you.
Identify the companies, programs and investors in your defined market
Develop a nuanced understanding of your target sector with data and analysis
Understand trends and issues shaping the future of your target market
Create a refined target list of potential partners from full biopharma universe
Evaluate potential partners by exploring their pipelines, funding, deals and strategies
Prepare for meetings with both data and context
Identify translational science threats in relevant targets, diseases and technologies
Create alerts for product and strategic developments at competing companies
Monitor investments in your therapeutic and technology spaces
Use Company Profiles to identify comparable programs across the industry
Review investing and partnering deals in your pipeline or program space
Understand where your program fits in the industry pipeline
Phase I data reignite enthusiasm for checkpoint inhibitors, but will the results reproduce?
The landscape for Duchenne muscular dystrophy gene therapies; plus insights from FDA’s Peter Marks and priorities for Monica Bertagnolli
BioCentury's Distillery Dashboard is a searchable database summarizing translational papers from over 25 top journals, with new innovations added continuously. Search for targets, diseases and geographies of interest, and identify the investigators behind the work.
For three decades BioCentury has helped biotech executives and investors make business critical decisions and build larger networks with peers across the innovation ecosystem. In 2023, BioCentury hits the road to organize three educational and networking events in Amsterdam, London, and Boston. Launching this series is an in-depth interview with Europe’s top Regulator.
EMA agency issues positive opinions on Pylclari and Ztalmy, label expansions for Opdivo and Sogroya
“When it comes to timely, relevant discussion of complex industry issues, BioCentury provides fact-based, in-depth reporting and analysis, resisting sensationalism and often incorporating multiple perspectives. This allows us as readers to walk away informed, and in some cases, with actionable insights.”
“The quality and depth of BioCentury's reporting and analysis sets them apart from their competitors. BioCentury provides the most intelligent coverage of the pharma and biotech industry.”
“I’ve been a BioCentury reader for eons. I find other sources have good insights around individual companies or events, but few provide intelligent commentary that gives me a comprehensive sense for what’s happening in a broad area. BioCentury’s “context setting” is really value-added and what sets them apart.”